ASGCT Annual Meeting: Celebrating 25 Years in 2022
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting, celebrating its 25th year in 2022, is the premier event for professionals in gene and cell therapy. The four-day meeting—and one preceding day of Pre-Meeting Workshops—is the best place for people in the field to learn from the latest scientific research, stay up to date on new technologies, and make career-advancing connections with peers.
Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.
Register for virtual or in-person program here: https://annualmeeting.asgct.org/register.
ASGCT Annual Meeting 2022 NEWS
Taking cell therapy to the next level with 3D bioprinting of human tissues
June 6, 2022 -- Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer. Roos spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
June 6, 2022 -- Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer. Roos spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
Overcoming the blood-brain barrier for gene therapy delivery with AAV capsids
June 2, 2022 -- Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo Therapeutics. Pooler spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about how Sangamo’s adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier.
June 2, 2022 -- Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo Therapeutics. Pooler spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about how Sangamo’s adeno-associated virus (AAV) capsids are designed to overcome the blood-brain barrier.
Decibel Therapeutics develops treatments to restore and improve hearing, balance
May 31, 2022 -- Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD. Reid spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
May 31, 2022 -- Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD. Reid spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
May 27, 2022 -- Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Dr. Bruce Dezube, senior vice president at Mustang Bio, spoke to ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about the targeting of the CD20 antigen.
May 27, 2022 -- Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Dr. Bruce Dezube, senior vice president at Mustang Bio, spoke to ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting about the targeting of the CD20 antigen.
Graphite Bio sees its gene editing tech as step above CRISPR
May 26, 2022 -- While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect. CRISPR is the “cut” function and Graphite Bio’s technology is the “cut and paste” capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
May 26, 2022 -- While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct the underlying genetic defect. CRISPR is the “cut” function and Graphite Bio’s technology is the “cut and paste” capability, Lehrer told ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
May 26, 2022 -- Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously deliver a functional frataxin gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. At the American Society of Gene & Cell Therapy 2022 annual meeting, Lexeo presented new preclinical data supporting its FA cardiomyopathy program.
May 26, 2022 -- Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously deliver a functional frataxin gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. At the American Society of Gene & Cell Therapy 2022 annual meeting, Lexeo presented new preclinical data supporting its FA cardiomyopathy program.
COVID-19 mRNA-based vaccines benefit from decades of research
May 25, 2022 -- 25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in what would become a critical technology used in some of today’s COVID-19 mRNA-based vaccines. Weissman spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC about their research journey.
May 25, 2022 -- 25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in what would become a critical technology used in some of today’s COVID-19 mRNA-based vaccines. Weissman spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC about their research journey.
Next-generation AAV capsids hold key to developing life-changing therapies
May 24, 2022 -- Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional adeno-associated virus (AAV) serotypes in non-human primates, according to Todd Carter, PhD, senior vice president for research. The company presented data on the platform at the American Society of Gene & Cell Therapy 2022 annual meeting.
May 24, 2022 -- Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional adeno-associated virus (AAV) serotypes in non-human primates, according to Todd Carter, PhD, senior vice president for research. The company presented data on the platform at the American Society of Gene & Cell Therapy 2022 annual meeting.
Genenta Science reports preliminary results of Temferon-glioblastoma study
May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD. ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC, about Temferon.
May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD. ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC, about Temferon.
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
May 23, 2022 -- In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview of the company's development of novel treatments for inherited forms of blindness at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.
May 23, 2022 -- In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview of the company's development of novel treatments for inherited forms of blindness at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC.